Dr. Wendy Levin is a Hematologist and Oncologist with over 15 years of leadership in biotech and diagnostics, guiding clinical development from early research to FDA registration trials. She has held senior roles at both start-ups and Fortune 500 companies, leading regulatory strategy, clinical development, and biomarker research, and currently serves as Chief Medical Officer at Biofidelity. Her pivotal research at UCLA on HER-2/neu in breast and ovarian cancers contributed to the development of Herceptin, a breakthrough therapy in breast cancer care – this work has been recognized by the Lasker award and has been considered for nomination for the Nobel Prize.